Life insurance implications of mortality for up to 40 years after repair of congenital heart defects in childhood G R Cumming MD FRCPC CARDIOTHORACIC AND PAEDIATRICS SECTIONS, 13 JUNE 1997 Assuming an annual birth rate of 16 000 per million population, 1% having a congenital heart lesion, 50% of these requiring surgical intervention, with a 90% survival to adult years, there will be 72 new adults per year per million population with repaired heart defects; or, in a 20-year period for a population of 65 million persons, over 90 000 subjects. Most of these citizens will be symptom-free, hoping to start life on an equal footing with their peers, when seeking jobs, home mortgages, and financial services such as life, disability and health insurance. In this paper I review the long-term mortality in relation to life insurance.
When a person starts a job, he or she is usually eligible for employee benefit at entry, including insurance coverage, irrespective of his or her health record. Adults who have had heart surgery in the past will then have the same financial benefit as their peers. Individual insurance is another matter, since this is voluntary financial planning. Individuals are able to purchase large sums of insurance coverage, often exceeding £5 million. The mortality risk of individual applicants is assessed by medical underwriters with the aid of medical statistics and the advice of medical consultants. Applicants are assigned to risk categories starting at standard risk or multiples of a standard risk. In this system the standard mortality is assigned a value of 100%, twice normal mortality 200% and so on. Mortality ratio is the observed mortality divided by the expected mortality times 100, and where possible the Kaplan-Meier life table method is preferred. The objective of the underwriting process is to group persons of similar mortality into broad categories according to mortality ratios in multiples of 25-50% above standard. A further explanation of mortality rates and life insurance costs is provided in the Appendix.
Many insurers will decline coverage for clients with mortality ratios estimated at above 500%, but some insurers cover ratios even in excess of 1000%. While some consider it unfair to penalize those with health problems beyond their control by assigning them to high-risk categories, individual insurance would not exist without this system. If there was but one price for all, the cost of insurance would be priced out of reach of the majority, and only those with a strong likelihood of a shortened lifespan would find the product a useful financial vehicle. Those with potential increased mortality would load up with insurance, bankrupting the system a phenomenon referred to as antiselection.
Open heart repair of congenital heart defects started in 1954, and was in full swing in many centres around the world by 1960. There are excellent follow-up reports of the survivors of these early operations, now exceeding 35 years. These patients and their attending physicians are often disappointed that the insurance industry may not regard them as a normal risk. When examining mortality ratios it is essential to note that in the age group 1-40 years, any extra deaths will push these well above 100 because of the low death rate in the general population. The mortality at age 10 in the normal population is <0.2 per thousand per year, or 1 per thousand in 5 years, or 0.1%. If the mortality for repaired Fallot's tetralogy was 1% from age 10 to 15 years, this would represent a mortality ratio of 1000%.
Mortality studies are always a backward look at what has gone before, and the long-term studies that are summarized in this report concern patients operated on between 1955 and 1965, when cardiac surgery was in its infancy. Experience has honed diagnostic and surgical skills. With improved technical factors the early postsurgical mortality is far less now than it was in the pioneering days. It is to be expected that late mortality will also be reduced but this awaits the test of time. With surgery conducted in early infancy before the development of severe myocardial hypertrophy or fibrosis, with better myocardial protection, with more accurate diagnoses and more complete surgical corrections, with surgery carried out before the development of pulmonary vascular disease, with the elimination of palliative procedures that created additional anatomical changes, and with greater awareness of the problems leading to arrhythmias and their avoidance, there should be a considerable improvement in late mortality. A potentially negative factor is that patients with more severe lesions are now surviving surgery, and these patients may be expected to have more problems later on. Early mortality varies between surgeons and between centres, and perhaps late mortality is also institution-specific. We cannot assume that an improvement in early mortality necessarily means improvement in late mortality. There may be a honeymoon with low mortality 5-20 years after surgery with later mortality increasing because of myocardial failure or coronary artery disease. The low incidence of arrhythmias in patients operated on in infancy does not necessarily mean that these patients will still have a low incidence of arrhythmias when they reach 50 or 60 years of age.
A reference population is required for the calculation of mortality ratio. Reports from the Mayo Clinic and the Oregon study used local general population statistics. For studies not including a normal population, United States 1986 mortality tables were used. Ratios have been rounded off to 25% or 50% intervals. Insurance company standard mortality rates are as low as 40% of general mortality in the first few years of the policy because of the exclusion of those with disease or risk factors, and then approach the general population mortality after 5 to 10 years. In this review standard 1993 insurance mortality values were used for those clinical series where the mortality rate was obviously over 500%.
Most insurers accept 90% of applicants as standard risk, increase the premiums for 7% and decline the risk for 3% of applicants. In North America after age 20, four separate mortality tables are required male and female, smoker and non-smoker.
Here follows a summary of existing 25-30-year followup studies of patients having surgical repair of the common congenital heart defects, the data being condensed to mortality ratios only.
ATRIAL SEPTAL DEFECT: SEPTUM SECUNDUM AND SINUS VENOSUS TYPES
When repair is performed under age 20 or before the development of marked cardiac dilatation or arrhythmia, most cardiologists presume that mortality is no different from that in the general population. In fact, the Mayo Clinicl [25] [26] [27] [28] [29] [30] year follow-up for these lesions gave mortality ratios in the range of 150%. While the percentage deaths was considerably higher in the older age groups, the mortality ratios were the same. The patients were divided into two groups those with pulmonary artery pressures less than 40 mm Hg systolic, and those with pressures greater than 40 mm Hg systolic. In the group with pulmonary hypertension mortality ratios were 700% for those less than age 24 and 235% for those greater than age 24, but the number in each subgroup was small. In the Oregon follow-up study2 the mortality ratio for 25 years after repair of atrial septal defect was 225% for cases repaired up to age 18. From the Minneapolis long-term follow-up study3 the mortality ratio was 100%, i.e. the same as that of the normal population. Even in these early series mortality was close to normal, and with earlier repair and a lower incidence of atrial fibrillation, and possibly with reduced scarring with catheter closure techniques, near normal mortality is to be expected for cases repaired today and in the future.
VENTRICULAR SEPTAL DEFECT
The Natural History Study4 was a multicentre study with 25 years' follow-up of patients treated medically or surgically for three congenital lesions. Patients classified as Eisenmenger syndrome (based on pulmonary to systemic resistance ratios exceeding 0.7) had a mortality ratio during the 25 years of follow-up of over 1500%. Patients with large ventricular septal defects (VSDs) labelled as severe with pulmonary artery systolic pressures of 70% or more of systemic pressure and pulmonary/systemic flow ratios of 1.2 or greater, had a mortality ratio of 1100% in 25-year follow-up. At the time of the NHS-II study surgery was also performed in occasional patients with trivial VSD, 45% of patients with mild VSD, and 52% of those with moderate VSD, with a near-zero late mortality.
Moller et a].5 reported on the 30-year survival of 296 survivors of VSD surgery between 1954 and 1960. The overall mortality ratio for the entire series was about 750%. Increased pulmonary vascular resistance was an important determinant of high mortality, and if pulmonary vascular resistance was over 7 units 30-year mortality was 44%. Complete atrioventricular (A-V) block and even transitory A-V block postoperatively was associated with a high mortality.
In this Minneapolis series5 the excess mortality persisted with each decade of follow-up. 11% of patients died in the first 9 years, 5% in the next 10 years, and 6% in the last 10 years of follow-up. Five sudden deaths occurred in patients without pulmonary vascular disease 3, 8, 22, 29, and 33 years after surgery. This series was disappointing in that excess mortality not related to pulmonary vascular disease or other avoidable problems was still present after 20 years.
The data from the Mayo Clinic series6 of 191 VSD patients having surgery between 1956 and 1959 were analysed at intervals of 5 years after surgery. The mortality ratio was 1500% for the first 5 years. It was still 1000% for [11] [12] [13] [14] [15] years, but decreased to around 100% (standard mortality rate) after 20 years.
In the Oregon series2 312 patients with VSD repair followed for 25 years had a mortality ratio of about 333%. Whether the excess deaths in the earlier series will be completely eliminated in the cases repaired in infancy today requires the test of time.
PATENT DUCTUS ARTERIOSUS
Patients having ligation of patent ductus arteriosus are expected to have a normal subsequent long-term mortality unless there are some other underlying health problems. The actual mortality with over 25 years of follow-up in the Oregon study2 was 133% and the extra deaths were due to associated non-cardiac disorders. Most insurers offer standard insurance coverage for clients with repaired patent ductus, often assuming that pulmonary vascular disease was absent, closure was complete and there were no associated defects. Follow-up is lacking for closures obtained with catheter intervention but most insurers seem willing to chance a standard offer.
ISOLATED VALVULAR PULMONARY STENOSIS
The NHS-II7 investigators followed a large number of patients with pulmonary stenosis for 2-25 years. In those with initial gradients of less than 25 mm Hg there was no increase in the gradient, and over time 5% of these patients were sent for surgery with no late mortality. With gradients of 25-49mm Hg 20% eventually had surgery, and there were no late deaths here either. In those with gradients of 50-79 mm Hg, 34% had surgery within a year of entry into the study, and 68% by the last follow-up. There were no late deaths in the surgical group.
All patients with gradients of 80mm Hg or more had surgery in the NHS-II study, and also included in the surgery group were the patients with gradients of 50-79 mm Hg operated on in the first year after entry into the study. In those having surgery before age 12, there were no late deaths. For those operated on after age 12 who also had enlarged hearts, late mortality was 20%.
The Mayo Clinic8 reported their 25-year follow-up of patients having surgery for valvular pulmonary stenosis. The mortality ratio for those having surgery between ages 5 and 20 years was below 100%, i.e. better than that of the reference population. Under age 5 the mortality ratio was rather high (350%) since the series included sick infants at a time when these patients were not as well managed as they are today. For those with pulmonary stenosis having surgery after age 20 years, the Mayo Clinic mortality ratio exceeded 200%. These mortality ratios are higher than is generally stated for this simple lesion. Not all series had excess mortality; in the Minnesota series3 there was only one late death among those surviving surgery for valvular pulmonary stenosis, while in the Oregon study2 after 25 years the mortality was equal to the expected. Most patients after successful relief of pulmonary stenosis either by surgery or by balloon valvuloplasty are offered near-standard or only slightly rated policies. Caution is required for those with severe pulmonary regurgitation and dilated right ventricles, especially if there is some tricuspid insufficiency.
VALVULAR AORTIC STENOSIS
The NHS-II investigators2 followed a large population with various degrees of severity of aortic stenosis for 25 years. Of those with initial gradients of under 25 mm Hg, 21% required surgery by 25 years because of deterioration. This is in contrast to mild pulmonary stenosis which did not worsen with time. In subjects with gradients of less than 50mmHg at the entry to the study the 25-year mortality was about 200%. In subjects with initial peak gradients greater than 50 mm Hg the mortality ratio after 25 years was 530%. In the Oregon series2 the mortality ratio of those having surgery for congenital aortic stenosis followed for 25 years was 525%. In the Minnesota series with 30year follow-up the mortality ratio of those having aortic stenosis classified as simple was 150% and for complex 300%3.
The above values did not include patients with extremely severe aortic stenosis requiring intervention in infancy, in whom the long-term mortality ratio was over 1000%.
Congenital aortic stenosis requiring surgical or catheter intervention in childhood is regarded by most insurers as a treacherous lesion. Subjects with all factors favourable are able to purchase insurance at about 250% mortality ratio after age 40 years, or in about the same range as survivors of valve replacement with excellent results.
COARCTATION OF THE AORTA
In an early series of 248 patients operated on at Johns Hopkins10 at an average age of 20 years and followed for 11-25 years, 12% of the patients died at an average age of 35 years (ruptured aorta, ruptured cerebral aneurysm, coronary artery disease, sudden death). The average annual mortality rate was 0.7%, giving a high mortality ratio. Simon and Zlotoll reviewed 241 patients having surgery at an average age of 12 years followed for 6 years and 6% were dead at the average age of 32 years.
In a large series from the Mayo Clinic12 432 patients were followed for 10 years with a mortality ratio of 450%, 259 for another 10 years with a mortality ratio of 266%, and 53 for another 10 years with a mortality ratio of 2 36%.
With the current practice of repair under age 5 years, long-term survival will probably improve. Some insurers seem to regard coarctation of the aorta as benign and do not properly assess the risk with arm leg pressure comparison, exercise pressures, coronary risk factors, presence of aortic valve lesions, and the published survival data.
TETRALOGY OF FALLOT
As for other lesions, the Mayo Clinic series13 is ideal for calculating mortality ratios for Fallot's tetralogy. The data are presented by use of life table analysis including mortality in a comparative normal population. Patients with postoperative complete heart block were excluded because adequate pacing was not available in the early years of this study. The mortality ratios can be calculated at 5-year intervals of follow-up and start out at 2700% for the first 5 years, 670% for the next 5 years, and then 220, 325, 275, and 150% for the succeeding 5-year intervals. Mortality ratio by age 40 or so was only slightly above the normal mortality at this time probably because the number of cardiac deaths declined, the patients with more severe residual disease having succumbed, and because of the higher mortality in the normal population at this age. Higher overall mortality ratios were observed for those with shunts Blalock-Taussig shunts 350%, Potts or Waterston shunts 900%, no shunts 325%. Mortality ratios were also related to the use of outflow tract patching: 260% for no patch, 400% for a partial patch, and 500% for a full patch. The 25-year mortality ratio in the Oregon series2 of 118 patients was 2 80%.
It is well to remember that the surgical mortality was high in these early years, and in the Minneapolis series3 27% of the patients succumbed in the perioperative period. In the survivors followed for up to 30 years the mortality rate was 33%, giving a very high mortality ratio. survival was 94% at 5 years, 87% at 10 years and 83% at 20 years. The interval mortality from 5 to 10 years was 7.4% (mortality ratio over 2000%) and the interval mortality from 11 to 20 years was 4.6% (mortality ratio around 500% compared with an insurance population). Patients with transposition of the great arteries (TGA) having the Mustard procedure at Great Ormond Street were followed for a mean of 11.6 years16. Interval mortality from 1 to 10 years after surgery was 11.7% and from 11 to 20 years 10.6%, corresponding to mortality ratios of over 2000%. Atrial flutter was a risk factor for sudden death.
The experience with the Mustard procedure at the Sick Children's Hospital in Toronto has been divided into an early series 1963-1973 and a later series 1974X198517. In the 95 operative survivors in the first series there was a very high attrition rate in the first 5 years and an overall mortality at the end of the follow-up period of 22% giving a mortality ratio exceeding 5000%. In the later series the 10- year mortality in the survivors was 4.5%, giving a mortality ratio of about 1800%. The encouraging result was a complete absence of deaths between 5 and 10 years of follow-up, suggesting that late deaths would be uncommon in the second series; in the hands of the Toronto group these survivors would come into the insurable range. Some caution is necessary, however, because in the first series the mortality rate from 5 to 10 years was only 2.6%, but in the next 10 years of follow-up the mortality rate was 20%. In Toronto, for simple TGA post-Mustard patients referred to an adult cardiology clinic at age 18-20, mortality in the next 12 years has been about 10%. For male non-smokers this equates to a mortality ratio of over 1000%.
Medium-term results after the arterial switch operation for TGA are available for 470 patients operated on at the Children's Hospital of Boston18. Survival was 93% at 30 days, 92% at 1 year, 91% at 5 years, and 91% at 8 years, so there were no deaths after 5 years. 6% of patients required second procedures to correct pulmonary artery stenosis. The 1.1% mortality between 1 and 5 years represents a mortality ratio of over 500%. While it is encouraging that there were no deaths in this series from 5 to 8 years, and it appears that patients surviving the switch operation for 5 years are entering the insurable range of mortality, some problems have been reported with the coronary circulation. Because of the late mortality in TGA patients having the Mustard operation the Toronto group changed to the switch operation in 1985 and have performed about 500 such procedures. Most of the patients in this series are still under 10 years of age. The late mortality for the uncomplicated cases is about 0.3% per year, much better than the Mustard results. This still calculates out to a mortality ratio of about 1000%, and mortality after age 10-15 years is as yet unknown. There has been next to no arrhythmia, cases of right or left ventricular dysfunction have been few, and there is promise that late mortality may not be much greater than in the general population, but follow-up needs to continue for at least another 20 years to show this. Most insurers will choose to postpone individual life insurance coverage for these subjects, or to place the best cases in a high-risk category.
THE FONTAN OPERATION
The Mayo Clinic has reported improved results with the Fontan procedure in cases coming to surgery after 198720. For example, survival at the 1-year point after surgery was 79% in their early series and 88% in the more recent series. However, the subsequent mortality between 1 and 5 years was 8.0% in the recent series compared with 7.6% in the earlier series, so while the operative and early mortality improved, the late mortality did not. The mortality ratio for this difficult group still exceeds 2000%. The long-term outlook even in the most favourable cases with tricuspid atresia is uncertain, and most insurers do not consider these cases insurable at present.
ATRIOVENTRICULAR CANAL
Bando et al. reported on 203 patients coming to surgery for complete atrioventricular canal from 1984 to 199521. The early perioperative mortality was 7.9%. Mortality between 1 and 10 years was only 0.9%, but this still represents a mortality ratio of over 400%. The residual mitral regurgitation was trivial or mild in 94% so that excellent results were obtained and the long-term outlook would appear favourable, but until the follow-up reaches 30-40 years the ultimate mortality will be uncertain. The best cases will probably receive insurance offers in the 200% mortality range.
THE INSURER'S DILEMMA
Published reports do not always allow confirmation that weeding out of potentially higher risk subjects would be successful since there were insufficient numbers of patients to subdivide the diagnostic groups into fine-tuned categories of risk. By eliminating individuals with potentially adverse features including pulmonary vascular disease, atrioventricular block or history of temporary heart blocks, residual septal defects, incomplete repairs, residual right ventricular outflow obstruction, poor myocardial function, low exercise capacity, tricuspid regurgitation or arrhythmias, insurers can pick those expected to have near-normal mortality from the overall postoperative survival group. Meta-analysis with large cohorts of patients followed for 70+ years with groups stratified into those with and without perceived risk factors should show in the future which subjects will come close to having normal life expectancy. Such data will require at least another 30 years to surface. How these patients will contend with coronary heart disease or the increasing incidence of arrhythmia with ageing is anyone's guess. The insurance industry is competitive, with many companies wanting to capture the premium income, so insurance offers tend to be better than the published statistics would support. Part of the reason is that insurers are optimistic that results will continue to improve.
The growing population of adults with congenital heart defects has led to the establishment of special clinics to follow them, but whether this will alter the mortality in those who are symptom-free and are the likely purchasers of individual insurance is not known. APPENDIX Table I , the 30-year-old smoker 165% of non-smoker rates. These rates vary from company to company and country to country, and are quite different depending on the nature of the insurance contract. The extra premium required for rated policies generally follows the mortality ratio. It is also somewhat dependent on the amount of insurance applied for. Premium increases are approximately 190, 285, 360, and 435% above standard premium for mortality ratios of 200, 300, 400, and 500%, respectively. When a patient is asked to pay three times the normal premium he or she may think this translates into an expected very early death. Table 2 is a useful way for the clinician and the patient to realize that a high mortality ratio does not indicate an early demise. In Table 2 the expected longevity in years is provided for ages 10 to 60, at mortality ratios of up to 500% based on insurance mortality figures. When a 20-year old is advised that his mortality ratio has been assessed at 300%, it is useful to point out that this means 47.1 years' lifespan or survival to 67. Table 3 is also a useful presentation for the clinician. Mortality rates of various medical studies are often presented in per cent over a given period of years. For a 10-year follow-up Table 3 indicates the mortality ratio for 1 to 10% mortality rates at ages 10-40 years. A 5% mortality in a 10-year follow-up provides a mortality ratio of 926% at age 10 but only 445% at age 40.
